한글목차

동반진단약 시장 규모는 최근, 비약적으로 확대하고 있습니다. 2025년 86억 9,000만 달러에서 2026년에는 105억 4,000만 달러로, CAGR 21.3%로 성장이 전망되고 있습니다. 지난 수년간의 성장 요인으로는 표적 암 치료의 발전, 종양학 임상시험의 확대, 제약사와 진단 기업 간의 협력 강화, 암 발생률 증가, 동반 진단 검사의 규제 승인 등을 꼽을 수 있습니다.

동반진단 시장 규모는 향후 수년간 급격한 성장이 전망되고 있습니다. 2030년에는 227억 달러에 달하며, CAGR은 21.1%에 달할 전망입니다. 예측 기간 중의 성장에는 개인 맞춤형 치료 선택에 대한 수요 증가, 정밀의료에 대한 투자 확대, 면역종양학 파이프라인 확대, AI 기반 진단 해석의 보급 확대, 규제 당국의 진단약 공동개발에 대한 강조 강화 등이 요인으로 작용할 것으로 예측됩니다. 예측 기간의 주요 동향으로는 정밀 종양 진단의 채택 확대, 의약품 개발에서 동반 진단의 통합 증가, 차세대 염기서열 분석(NGS) 기반 진단 플랫폼의 활용 확대, 바이오마커 기반 치료법의 확대, 맞춤형 의료에 대한 집중도 강화 등을 들 수 있습니다.

표적치료제 증가가 동반진단 시장의 성장을 촉진할 것으로 예측됩니다. 표적치료제는 암세포의 특정 특성에 초점을 맞추어 질병의 증식 및 확산을 지연시키는 약리학적 접근법을 말합니다. 이 약제들은 체내에서 순환하지만 화학요법보다 정밀한 효과를 발휘하고 부작용이 적은 경우가 많습니다. 생물학적 마커에 기반한 동반진단 검사는 개인 맞춤형 암 치료의 중요한 요소로 자리 잡고 있습니다. 예를 들어 2024년 2월 미국 기반 병원 및 헬스케어 관련 단체인 '맞춤의료연합'이 발표한 바에 따르면 2023년 FDA가 승인한 희귀질환 환자를 위한 신규 맞춤치료제는 16건으로 2022년 6건보다 증가했다고 합니다. 이 때문에 표적 치료 증가가 동반진단 시장의 성장을 가속하고 있습니다.

동반진단 시장의 주요 기업은 맞춤형 의료 강화, 환자 결과 개선, 표적치료 효과 최적화를 위한 혁신적인 치료 솔루션 창출을 위해 협력을 강화하고 있습니다. 이러한 기업 간 협력은 혈액학 및 종양학 치료용 동반진단(CDx)의 개발 및 상용화를 가속화할 것입니다. 예를 들어 2024년 1월 캘리포니아에 본사를 둔 실험실 장비, 소프트웨어, 서비스, 소모품을 제공하는 아젠트 테크놀러지스(Agent Technologies)는 미국 제약회사 인사이트(Insight)와의 제휴를 발표했습니다. 이번 협력을 통해 아젠트의 동반진단제(CDx) 개발 전문성과 실적이 결합되어 인사이트의 혈액학 및 종양학 포트폴리오를 지원하게 됩니다. 이를 통해 애질런트는 새로운 바이오마커로 CDx 포트폴리오를 확장하고, 인사이트는 애질런트의 분석법 개발, 규제 당국 승인 및 상업화 전문성을 활용하여 미국 및 유럽에서 임상시험 및 CDx 등록을 촉진할 수 있게 되었습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 용도 산업의 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의에 의한 공급망에 대한 영향, Covid가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장의 세계 TAM(Total Addressable Market)

제9장 시장 세분화

제10장 지역별·국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 대기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 합병과 인수

제40장 시장의 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Companion diagnostics refer to in vitro diagnostic medical tests employed to assess the safety and effectiveness of a corresponding drug or biological product. These tests play a crucial role in helping healthcare professionals match patients with specific drugs or therapies.

The primary products and services in the companion diagnostics market include assays, kits, reagents, software, and related services. Assays, kits, and reagents find applications in various life science, environmental, and research laboratories. Assays are procedures used to examine substances for composition or quality, kits are collections of equipment and materials for specific purposes, and reagents are chemicals used in laboratory testing. Technologies such as polymerase chain reaction, next-generation sequencing, in situ hybridization, and immunohistochemistry are employed in companion diagnostics. These diagnostic tools are instrumental in identifying various cancer diseases like lung, breast, colorectal, leukemia, and melanoma. The primary users of companion diagnostics include pharmaceutical and biopharmaceutical companies, reference laboratories, and contract research organizations.

Tariffs are influencing the companion diagnostics market by increasing costs of imported reagents, sequencing instruments, assay kits, software platforms, and laboratory consumables. Pharmaceutical companies and reference laboratories in North America and Europe are most affected due to reliance on specialized imported technologies, while Asia-Pacific faces higher export-related costs. These tariffs are raising development and testing expenses and extending commercialization timelines. However, they are also encouraging regional diagnostic manufacturing, local software development, and stronger domestic diagnostics ecosystems.

The companion diagnostics market research report is one of a series of new reports from The Business Research Company that provides companion diagnostics market statistics, including companion diagnostics industry global market size, regional shares, competitors with a companion diagnostics market share, detailed companion diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the companion diagnostics industry. This companion diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The companion diagnostics market size has grown exponentially in recent years. It will grow from $8.69 billion in 2025 to $10.54 billion in 2026 at a compound annual growth rate (CAGR) of 21.3%. The growth in the historic period can be attributed to growth in targeted cancer therapies, expansion of oncology clinical trials, increased collaboration between pharma and diagnostics firms, rising cancer incidence rates, regulatory approvals for companion tests.

The companion diagnostics market size is expected to see exponential growth in the next few years. It will grow to $22.7 billion in 2030 at a compound annual growth rate (CAGR) of 21.1%. The growth in the forecast period can be attributed to increasing demand for personalized treatment selection, rising investments in precision medicine, expansion of immuno-oncology pipelines, growing adoption of ai-driven diagnostic interpretation, increasing regulatory emphasis on diagnostic-drug co-development. Major trends in the forecast period include increasing adoption of precision oncology diagnostics, rising integration of companion diagnostics in drug development, growing use of ngs-based diagnostic platforms, expansion of biomarker-driven therapies, enhanced focus on personalized medicine.

The rising number of targeted therapies is anticipated to drive the growth of the companion diagnostics market. Targeted therapy refers to a pharmacological approach that focuses on specific characteristics of cancer cells to slow down the disease's growth and spread. While these medications circulate throughout the body, they have a more precise effect than chemotherapy and often result in fewer side effects. Companion diagnostic testing based on biological markers is becoming a crucial component of personalized cancer care. For example, in February 2024, the Personalised Medicine Coalition, a US-based hospital and healthcare organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, compared to six in 2022. Consequently, the increase in targeted therapies is fueling growth in the companion diagnostics market.

Major players in the companion diagnostics market are joining forces to create innovative treatment solutions aimed at enhancing personalized medicine, improving patient outcomes, and optimizing the effectiveness of targeted therapies. This collaboration among companies will accelerate the development and commercialization of companion diagnostics (CDx) for hematology and oncology treatments. For instance, in January 2024, Agilent Technologies, Inc., a California-based company providing instruments, software, services, and consumables for laboratories, announced a partnership with Incyte, a US-based pharmaceutical company. This collaboration combines Agilent's expertise and established track record in developing companion diagnostics (CDx) to support Incyte's hematology and oncology portfolio. As a result, Agilent will expand its CDx portfolio with new biomarkers, while Incyte will leverage Agilent's proficiency in assay development, regulatory approvals, and commercialization to facilitate clinical trials and CDx registration in the U.S. and Europe.

In September 2023, Exact Sciences, a US-based provider of molecular diagnostics and precision oncology tests, acquired Resolution Bioscience for an undisclosed amount. Through this acquisition, Exact Sciences seeks to strengthen its companion diagnostic capabilities by integrating Resolution Bioscience's ctDx FIRST liquid biopsy platform and broadening its portfolio of precision oncology assays. Resolution Bioscience is a US-based company that offers next-generation sequencing (NGS)-based liquid biopsy tests to detect actionable tumor mutations and support targeted therapy.

Major companies operating in the companion diagnostics market are F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Amoy Diagnostics Co. Ltd., Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sysmex Corporation, Ventana Medical Systems

North America was the largest region in the companion diagnostics market in 2025. The regions covered in the companion diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the companion diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The companion diagnostics market includes revenues earned by theranostics and monitoring tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Companion Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses companion diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for companion diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The companion diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product And Service: Assays; Kits And Reagents; Software And Services
• 2) By Technology: Polymerase Chain Reaction; Next-Generation Sequencing; In Situ Hybridization; Immunohistochemistry
• 3) By Indication: Lung Cancer; Breast Cancer; Colorectal Cancer; Leukemia; Melanoma
• 4) By End-User: Pharmaceutical And Biopharmaceutical Companies; Reference Laboratories; Contract Research Organizations
• Subsegments:
• 1) By Assays: Polymerase Chain Reaction (PCR) Assays; Immunohistochemistry (IHC) Assays; Next-Generation Sequencing (NGS) Assays; In Situ Hybridization (ISH) Assays
• 2) By Kits And Reagents: Diagnostic Kits; Detection Reagents; Control Reagents
• 3) By Software And Services: Data Analysis Software; Interpretation Software; Custom Development Services; Consulting and Support Services
• Companies Mentioned: F Hoffmann-La Roche Ltd.; Agilent Technologies Inc.; Qiagen NV; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.; Amoy Diagnostics Co. Ltd.; Danaher Corporation; Guardant Health Inc.; Illumina Inc.; Myriad Genetics Inc.; Siemens Healthcare GmbH; Almac Group; Caris Life Sciences; Cepheid Inc.; Diaceutics plc; Epic Sciences Inc.; Foundation Medicine Inc.; Genomic Health Inc.; Grail Inc.; Hologic Inc.; HTG Molecular Diagnostics Inc.; Inivata Ltd.; Invivoscribe Inc.; MolecularMD Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Personal Genome Diagnostics Inc.; Precision Therapeutics Inc.; Prometheus Laboratories Inc.; Sysmex Corporation; Ventana Medical Systems
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Companion Diagnostics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Companion Diagnostics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Companion Diagnostics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Companion Diagnostics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Fintech, Blockchain, Regtech & Digital Finance
• 4.2. Major Trends
  • 4.2.1 Increasing Adoption Of Precision Oncology Diagnostics
  • 4.2.2 Rising Integration Of Companion Diagnostics In Drug Development
  • 4.2.3 Growing Use Of Ngs-Based Diagnostic Platforms
  • 4.2.4 Expansion Of Biomarker-Driven Therapies
  • 4.2.5 Enhanced Focus On Personalized Medicine

5. Companion Diagnostics Market Analysis Of End Use Industries

• 5.1 Pharmaceutical Companies
• 5.2 Biopharmaceutical Companies
• 5.3 Reference Laboratories
• 5.4 Contract Research Organizations
• 5.5 Academic Medical Centers

6. Companion Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Companion Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Companion Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Companion Diagnostics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Companion Diagnostics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Companion Diagnostics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Companion Diagnostics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Companion Diagnostics Market Segmentation

• 9.1. Global Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Assays, Kits And Reagents, Software And Services
• 9.2. Global Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry
• 9.3. Global Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma
• 9.4. Global Companion Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations
• 9.5. Global Companion Diagnostics Market, Sub-Segmentation Of Assays, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays
• 9.6. Global Companion Diagnostics Market, Sub-Segmentation Of Kits And Reagents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diagnostic Kits, Detection Reagents, Control Reagents
• 9.7. Global Companion Diagnostics Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services

10. Companion Diagnostics Market Regional And Country Analysis

• 10.1. Global Companion Diagnostics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Companion Diagnostics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Companion Diagnostics Market

• 11.1. Asia-Pacific Companion Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Companion Diagnostics Market

• 12.1. China Companion Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Companion Diagnostics Market

• 13.1. India Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Companion Diagnostics Market

• 14.1. Japan Companion Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Companion Diagnostics Market

• 15.1. Australia Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Companion Diagnostics Market

• 16.1. Indonesia Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Companion Diagnostics Market

• 17.1. South Korea Companion Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Companion Diagnostics Market

• 18.1. Taiwan Companion Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Companion Diagnostics Market

• 19.1. South East Asia Companion Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Companion Diagnostics Market

• 20.1. Western Europe Companion Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Companion Diagnostics Market

• 21.1. UK Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Companion Diagnostics Market

• 22.1. Germany Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Companion Diagnostics Market

• 23.1. France Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Companion Diagnostics Market

• 24.1. Italy Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Companion Diagnostics Market

• 25.1. Spain Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Companion Diagnostics Market

• 26.1. Eastern Europe Companion Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Companion Diagnostics Market

• 27.1. Russia Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Companion Diagnostics Market

• 28.1. North America Companion Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Companion Diagnostics Market

• 29.1. USA Companion Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Companion Diagnostics Market

• 30.1. Canada Companion Diagnostics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Companion Diagnostics Market

• 31.1. South America Companion Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Companion Diagnostics Market

• 32.1. Brazil Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Companion Diagnostics Market

• 33.1. Middle East Companion Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Companion Diagnostics Market

• 34.1. Africa Companion Diagnostics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Companion Diagnostics Market, Segmentation By Product And Service, Segmentation By Technology, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Companion Diagnostics Market Regulatory and Investment Landscape

36. Companion Diagnostics Market Competitive Landscape And Company Profiles

• 36.1. Companion Diagnostics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Companion Diagnostics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Companion Diagnostics Market Company Profiles
  • 36.3.1. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Qiagen NV Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Abbott Laboratories Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Companion Diagnostics Market Other Major And Innovative Companies

• Amoy Diagnostics Co. Ltd., Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc.

38. Global Companion Diagnostics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Companion Diagnostics Market

40. Companion Diagnostics Market High Potential Countries, Segments and Strategies

• 40.1 Companion Diagnostics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Companion Diagnostics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Companion Diagnostics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer